Navigation Links
Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Date:10/27/2009

FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2009 net sales of $535.2 million, a 9 percent increase compared to net sales of $489.7 million for the third quarter 2008. Basic income per common share for the quarter was $1.38. Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $1.70, an increase of 25 percent over the comparable figure of $1.36 for the same period in 2008. Adjusted net income for the third quarter of 2009 was $126.7 million, a 36 percent increase over the comparable $92.9 million for the third quarter of 2008. This exceeded the company's adjusted net income guidance range of $108 to $116 million.

Central nervous system (CNS) franchise net sales were $291.9 million during the quarter, a 7 percent increase compared to the same period last year. Pain franchise reported net sales of $116.3 million, a 1 percent decrease versus third quarter 2008. Oncology franchise net sales were $83.1 million, a 58 percent increase over the same period last year due to strong sales of TREANDA® (bendamustine hydrochloride) of $54.5 million.

During the quarter Cephalon recorded net cash provided by operating activities of $203.6 million bringing the year-to-date cash flow from operations to $517.1 million.

"The exceptional launch of NUVIGIL was the highlight of the quarter," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "In addition, we have assembled the deepest and most diverse pipeline in our history with a variety of small molecules and biologics being studied for pain, oncology, and inflammatory diseases. We look forward to developing this diverse pipeline with the goal of creating important new medicines for patients."

The company is updating its guidance for 2009.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Feb. 9 Palatin Technologies, ... the completion of first cohort dosing in a ... treatment for sexual dysfunction.  The primary endpoint in ... pressure effects of subcutaneous bremelanotide in men between ... also evaluate consistency of plasma exposure of bremelanotide ...
(Date:2/9/2010)... LAUSANNE , Switzerland , February ... Swiss-based global biopharmaceutical group of companies with,a ... that target unmet medical,needs, today announced the ... for the development, manufacture and commercialisation of ... inhibitor with a,potent anti-hepatitis C virus (HCV) ...
(Date:2/8/2010)... Calif. , Feb. 8 PreXion, ... quality 3D Cone Beam Imaging systems for dentistry, today ... as Director of Marketing. ,, PreXion President/COO ... Keith on our senior management team and I look ... extensive sales and marketing leadership, experience and success in ...
Breaking Medicine Technology:Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3PreXion, Inc. Announces Appointment of Director of Marketing 2Icahn Indicates That Biogen Board Refuses To Close Polls 12450 1MDCT angiography leads to successful treatment of severely blocked arteries in the legs 47804 1Biologists consider unifying framework to explain evolutionary puzzles 8709 1Biologists consider unifying framework to explain evolutionary puzzles 8709 2
... Inc. (OTC Bulletin Board: PLCSF), a company focused on ... that the first data from its pilot safety trial ... at the American College of Cardiology Annual Conference, on ... Florida. The poster will be presented by Dr. ...
... Abstracts Will Be Featured at Annual Kidney Care MeetingEL ... provider of kidney care services for those diagnosed with ... DaVita Clinical Research(R), today announced that company representatives will ... Spring Clinical Meetings scheduled for March 25-29, 2009 in ...
Other Medicine Technology:RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009 2RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009 3DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 2DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 3DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 4DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 5
(Date:2/9/2010)... Age, gender, genetics affect odds of remaining recurrence-free, research ... U.S. scientists have discovered there are genetic profiles that ... cancers, and those profiles differ depending on the age ... genetic and clinical data from 787 patients who were ... or above age 70). The findings are published in ...
(Date:2/9/2010)... folic acid, high blood pressure restrict fetal growth, study ... lifestyle habits you bring into pregnancy can have lasting ... A Dutch study found that women who smoked, had ... early pregnancy had babies that were smaller in the ... of complications later. , "Our study demonstrates that several ...
(Date:2/9/2010)... The following statement is ... M.D., President, American Medical Association: ,, (Logo: ... Medical Association is pleased to support First ... Let,s Move Campaign. As the nation,s largest ... address obesity and are committed to reenergizing ...
(Date:2/9/2010)... in captivity primarily for their skins, but some restaurants ... A study shows that eating these animals can have ... eating this ,delicacy., , Parasites, bacteria and viruses, and ... residues of veterinary drugs- eating reptile meat can cause ... a study published in the International Journal of ...
(Date:2/9/2010)... Dr. Franois Robert, a researcher at the Institut de ... team of Dr. Daniel Durocher (Samuel Lunenfeld Research Institute ... mapped all the fragile sites of a living organism, ... used by the researchers can be applied to humans. ... scientific journal Nature Structural and Molecular Biology . ...
Breaking Medicine News(10 mins):Health News:Genes Play Role in Prognosis With Non-Small Cell Lung Cancers 2Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 2Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 3Health News:Study carried out into biological risks of eating reptiles 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 3
... study neurosurgeons say they are now convinced that helmets ... the past have suggested wearing helmets during a motorcycle ... of skull base and cervical-spine (or neck) injuries secondary ... researchers to study whether helmets harm or hurt adolescent ...
... women with leukemia who died after receiving a bone marrow ... shows evidence of the transplanted // cells up to six ... marrow cells were actually acting as stem cells -- basic ... the body, and once thought to be found only in ...
... by adding more calcium to the diet may help reduce ... ,In a study of more than 95,000 women who never ... the eight years of the study. Women who consumed the ... stones compared to women who consumed the least amount. The ...
... United States. Investigators have been tracking the health of men and ... factors might impact their risk for heart disease and stroke. In ... and without a history of stroke.About 20 percent of the people ... of those who didn’t have a stroke. ,A good way ...
... suffer a stroke. About one-third of those strokes are recurrent. ... that consume lots of energy, such as dressing, bathing, walking ... survivors should be urged to exercise more at least 20 ... can help reduce the risk of another stroke. Strength training, ...
... a human papillomavirus ( HPV ) vaccination with cervical cancer ... all cervical cancers. According to a recent study it was ... caused by HPV, and 9 percent are preceded by persistent ... detect cervical cancer but it is not available to all ...
Other Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: